ESC 365 - The cost-effectiveness of sacubitril/valsartan (LCZ696) in the treatment of patients with heart failure with reduced ejection fraction in Norway

ESC Premium Access

The cost-effectiveness of sacubitril/valsartan (LCZ696) in the treatment of patients with heart failure with reduced ejection fraction in Norway

Session: Pharmacologic approaches in HF: could we do better?

Topic: Heart failure, other

Event: ESC Congress 2016

Congress Presentation

Add to my library

9 more presentations in this session

The risk of atrial fibrillation with ivabradine treatment: A meta-analysis with trial sequential analysis of over 40000 patients

Speaker: Associate Professor I. Tanboga (Istanbul, TR)

Differential impacts of digoxin modulated by volume status on one-year mortality in patients with acute heart failure

Speaker: Doctor W. Wang (Taipei, TW)

Dosage-dependent association between betablocker therapy with Carvedilol or Metoprolol and the risk of appropriate ICD therapy in primary prevention ICD patients.

Speaker: Doctor A. Huth Ruwald (Copenhagen, DK)

Effect of in-hospital treatment on short-term mortality of elderly versus non-elderly patients hospitalized for acute heart failure

Speaker: Doctor S. Katsanos (Athens, GR)

Potential clinical application of LCZ696 in patients with chronic heart failure in real life clinical practice: results from TREAT HF Study

Speaker: Professor Y. Cavusoglu (Eskisehir, TR)

Access the full session

Pharmacologic approaches in HF: could we do better?

Speakers: Associate Professor I. Tanboga, Doctor W. Wang, Doctor A. Huth Ruwald, Doctor S. Katsanos, Professor Y. Cavusoglu

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources